VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to compare the efficacy of the probiotic VSL#3 versus
placebo, in addition to standard maintenance drugs, in maintaining remission in Crohn's
disease (CD).
The secondary objectives are:
- To determine the time till flare of CD patients on VSL#3 compared to placebo.
- To assess whether concurrent therapy with VSL#3 leads to an improvement in the quality
of life (QOL).
- To assess whether concurrent therapy with VSL#3 reduces the severity of a flare if it
occurs.